NCT07107516|RecruitingPhase 1DMCFDA Drug
Phase 1b Ascending Dose Study of PanChol in Healthy Volunteers
PanChol
Safety and Immunogenicity of PanChol, a Novel Live Attenuated Oral Cholera Vaccine, in Zambia Adults
Loading search results
Sponsor study identifier
interventional
32
1 country
1
Study Start
May 20, 2026
Actual (reported)Primary Completion
November 30, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
January 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Cholera is a serious diarrheal disease that can be fatal within hours of onset. The current available cholera vaccines to prevent the disease are not very effective. Panchol is a new oral cholera vaccine that may be an improvement over the currently available vaccines in use. The goal of this study is to learn safety of this new oral cholera vaccine and the body's immune response to the vaccine. The researchers will compare the PanChol vaccine to placebo to see the side effects experienced in participants. The participants will be adults aged between 18 and 55 years and they will be required to:
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 30, 2025
Actual (reported)August 6, 2025
Actual (reported)May 20, 2026
Actual (reported)November 30, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
January 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
vaccine safety
The incidence of solicited and unsolicited adverse events, including serious adverse events, following PanChol vaccination
14 days after vaccination
immunogenicity
180 days after vaccination
vaccine stool shedding
8 days after vaccination
exploratory- serum antibody changes
180 days after vaccination
exploratory- IgA and IgG secreting cell responses
180 days after vaccination
Exploratory- Microbiome modification
180 days after vaccination
The PanChol vaccine will be given at a dose of 2 x 10\^7 CFU in this arm
The PanChol vaccine will be given at a dose of 2 x 10\^8 CFU in this arm
Panchol is a novel live attenuated oral cholera vaccine. It is the first vaccine created with the variant El Tor background that is predominant in the world today. The vaccine has ten different genetic modifications to minimize reactogenicity but maintain the ability to colonize the intestine.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
CIDRZ Matero clinical reseach site
Lusaka, Lusaka Province, 10101, Zambia
First Submitted
July 30, 2025
First Posted
August 6, 2025
Study Start
May 20, 2026
Actual (reported)Primary Completion
November 30, 2026
EstimatedContact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
January 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 6, 2026
Record last verified: 2026-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: